Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
A pharmacist fills a prescription. Photo: Jeffrey Greenberg/UIG via Getty Images
As part of Trump's drug pricing plan, the administration wants to study whether drug copay coupons should be allowed in federal health care programs.
Why it matters: Federal kickback law prohibits pharmaceutical companies from offering drug coupons to Medicare and Medicaid patients because the coupons induce patients to choose certain medications even though cheaper alternatives might be available.
The quote: "Would there be circumstances under which allowing beneficiaries of federal health care programs to utilize copay discount cards would advance public health benefits such as medication adherence, and outweigh the effects on list price and concerns about program integrity? What data would support or refute this?"
Go deeper: How insurers are responding to copay coupons.